nonavalent HPV vaccine / Beijing Health Guard Biotech, R-Pharm - LARVOL DELTA

Safety, Tolerability, and Immunogenicity of a Recombinant Nonavalent Human Papillomavirus Vaccine (Escherichia coli) in Healthy Chinese Women Aged 18-45 Years: A Phase 1 Clinical Trial. (PubMed, Vaccines (Basel)) - "This new recombinant nonavalent HPV vaccine exhibits good tolerability and strong immunogenicity among women aged 18-45 years, supporting further efficacy studies in larger populations."

Journal • P1 data • Cervical Cancer • Oncology • Solid Tumor

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine (clinicaltrials.gov) - P3 | N=1260 | Active, not recruiting | Sponsor: Beijing Health Guard Biotechnology, Inc | Recruiting ➔ Active, not recruiting

Enrollment closed • Human Papillomavirus Infection • Infectious Disease • Oncology

A Phase III Trial to Evaluate the Immunogenicity and Safety of HPV Vaccine (clinicaltrials.gov) - P3 | N=1260 | Recruiting | Sponsor: Beijing Health Guard Biotechnology, Inc

New P3 trial • Human Papillomavirus Infection • Infectious Disease • Oncology

Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients (clinicaltrials.gov) - P2 | N=180 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2022 ➔ Mar 2023 | Trial primary completion date: Dec 2022 ➔ Mar 2023

Trial completion date • Trial primary completion date • Infectious Disease • Nephrology • Oncology • Solid Tumor • Transplantation

High-risk human papillomavirus genotype distribution among women with gynecology complaints in northwest Ethiopia. (PubMed, Infect Agent Cancer) - "HR-HPV infection was reportedly higher among women in the present study area. Based on our findings, we strongly recommend the nonavalent HPV vaccine for immunization and any HPV-based screening method to take into consideration the predominant genotypes circulating in the country. The role of multiple HPV infections in high-grade cervical lesions entails further study in Ethiopia."

Journal • Cervical Cancer • Gynecology • Human Immunodeficiency Virus • Infectious Disease • Oncology • Solid Tumor

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine (clinicaltrials.gov) - P2 | N=780 | Completed | Sponsor: Beijing Health Guard Biotechnology, Inc

New P2 trial • Infectious Disease • Oncology

A Phase I Trial to Evaluate the Safety and Tolerability Profile of HPV Vaccine (clinicaltrials.gov) - P1 | N=160 | Completed | Sponsor: Beijing Health Guard Biotechnology, Inc

New P1 trial • Infectious Disease • Oncology